Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweigh

Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and r

Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to tar

Bank of New York Mellon Corp bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) durin

Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically sig

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), toda

Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of indiv

CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutica

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outp

Tarsus Pharmaceuticals NASDAQ: TARS reported second-quarter growth in sales of its Demodex blepharit

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.43) per share which missed the

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.43 per share versus the Zac

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral

Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tars

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral

IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today

Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a

Caxton Associates LLP cut its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 6

TARS experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xd

Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and lowe

IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today

Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., addi

Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc.,

Tarsus acquires iRenix to add IRX-101, with Phase 3 planned for 2027, as William Blair calls the dea

HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to rais

HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS)

– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks befor

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due

Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outp

Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and ra

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the

Barclays analyst Glen Santangelo initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with

Mizuho analyst Graig Suvannavejh initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with